Kaleido Biosciences Inc
OTC:KLDO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Nibe Industrier AB
STO:NIBE B
|
SE |
Kaleido Biosciences Inc
Capital Expenditures
Kaleido Biosciences Inc
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kaleido Biosciences Inc
OTC:KLDO
|
Capital Expenditures
-$1.1m
|
CAGR 3-Years
28%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Capital Expenditures
-$4.8B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Capital Expenditures
-$1.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Capital Expenditures
-$2.6B
|
CAGR 3-Years
7%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-6%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Capital Expenditures
-$4.1B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-12%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Capital Expenditures
-$10.8B
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-21%
|
|
Kaleido Biosciences Inc
Glance View
Kaleido Biosciences, Inc. is a clinical-stage healthcare company, which engages in the provision of healthcare services. The company is headquartered in Bedford, Massachusetts and currently employs 76 full-time employees. The company went IPO on 2019-02-28. The Company’s product candidates are Microbiome Metabolic Therapies (MMTs), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of existing microbes. The company is advancing a pipeline of MMT candidates to address a range of diseases and conditions with unmet patient needs. KB109 and KB174 are the MMT candidates for development as prevention of infections caused by multi-drug resistant (MDR) bacteria. Nomination of these candidates resulted from their performance relative to a range of other MMTs in ex vivo screening of microbiome samples from healthy volunteers, as well as microbiome samples from intensive care unit patients in an experimental set-up that specifically focused on determining the potential of MMTs to decrease the relative abundance of a panel of pathogenic bacteria.
See Also
What is Kaleido Biosciences Inc's Capital Expenditures?
Capital Expenditures
-1.1m
USD
Based on the financial report for Dec 31, 2021, Kaleido Biosciences Inc's Capital Expenditures amounts to -1.1m USD.
What is Kaleido Biosciences Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-41%
Over the last year, the Capital Expenditures growth was 72%. The average annual Capital Expenditures growth rates for Kaleido Biosciences Inc have been 28% over the past three years , -41% over the past five years .
